A review of 2015 reveals some key trends in drug pharmaceutical manufacturer activity and provides some insights for the 2016 outlook. The following post organizes a few of those trends with links to healthcare influencers across the industry:
1. An FDA activity analysis from BioMedTracker via Forbes shows the increased percentage of new molecular entity approvals for 2015
2. CenterWatch lists out the products approved by the FDA in 2015. These approvals significantly affect the landscapes of several classes, including PCSK9s, antipsychotics and cystic fibrosis treatments.
3. The FDA Law Blog reveals the dramatic increase in first action approval rates during the past 20 years. 2015 marks the highest percentage in history.
4. The amount of application withdrawals hit a potential low in recent years, according to a review by the FDA Law Blog that specifically focused on safety and efficacy.